FDA's Shocking Approval: Rexulti Fast-Tracked Despite Deadly Risks

Investigation raises serious questions about the harm-benefit balance of Rexulti; the Decision may reverse efforts to reduce the use of antipsychotics in US care homes. During testing, the antipsychotic medication brexpiprazole (Rexulti) did not demonstrate a significant therapeutic effect and was

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for

FDA Fast Tracked Drugs Make Companies Billions on Unproven Claims

FDA Expedited Review Programs - Friends of Cancer Research

How the FDA approved an antipsychotic that failed to show a

Low-Dose Tramadol as an Off-Label Antidepressant: A Data Mining

FDA fast-tracking approval of new drugs — fewer trials, less info

Brexpiprazole (Rexulti) Approved for Alzheimer's Agitation

FDA's Shocking Approval: Rexulti Fast-Tracked Despite Deadly Risks

Accelerated Change: Understanding the FDA's Expedited Pathways

Drugs News - Page 2 of 15 - SciTechDaily

U.S. FDA Approved Drugs from 2015–June 2020: A Perspective

FDA fast-tracking approval of new drugs — fewer trials, less info

FDA fast-tracking approval of new drugs — fewer trials, less info

FDA's Shocking Approval: Rexulti Fast-Tracked Despite Deadly Risks

FDA's Fast-Track for Rexulti Raises Concerns